Amisulpride: A safe and effective option for the long-term treatment of patients with schizophrenia

International Journal of Psychiatry in Clinical Practice

Volumn 7, Issue 3, 2003, Pages 167-175

  Naber, Dieter ^a   Arlt, Josef ^a   Lambert, Martin ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Amisulpride; Atypical antipsychotic; Long term treatment; Schizophrenia

Indexed keywords

AMISULPRIDE; CHLORPROMAZINE; CLOZAPINE; FLUPENTIXOL; HALOPERIDOL; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZOTEPINE;

AMENORRHEA; ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDOCRINE DISEASE; EXTRAPYRAMIDAL SYMPTOM; FOLLOW UP; HUMAN; HYPERPROLACTINEMIA; IMPOTENCE; LONG TERM CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SCHIZOPHRENIA; SCORING SYSTEM; SEXUAL DYSFUNCTION; SIDE EFFECT; TARDIVE DYSKINESIA; TIME SERIES ANALYSIS; WEIGHT GAIN;

EID: 0141559077     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: 10.1080/13651500310001545     Document Type: Article

References (54)

1. Kopala LC (1996) Spontaneous and drug-induced movement disorders in schizophrenia. Acta Psychiatr Scand 94: 12-7.
2. Van Putten T (1974) Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 31: 67-72.
3. Van Putten T (1978) Drug refusal in schizophrenia: causes and prescribing hints. Hosp Community Psychiatry 29: 110-2.
4. Fenton WS, Blyeler CR, Heinssen RK (1997) Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 23: 637-51.
5. Hellewell J (2002) Patient's subjective experiences of antipsychotics. CNS Drugs 16: 457-71.
6. Karow A, Naber D (2002) Subjective well-being and quality of life under atypical antipsychotic treatment. Psychopharmacology 162: 3-10.
7. Voruganti L, Cortese L, Oyewumi L, Cernovsky Z, Zirul S, Awad A (2000) Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res 43: 135-45.
8. Colonna L, Saleem P, Dondey-Nouvel L et al (2000) Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Int Clin Psychopharmacol 15: 13-22.
9. Loo H, Poirier-Littre MF, Théron M et al (1997) Amisulpride vs placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry 170: 18-22.
10. Speller JC, Barnes TRE, Curson DA et al (1997) One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol. Br J Psychiatry 171: 564-8.
11. Carrière P, Bonhomme D, Lempérière T (2000) Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group). Eur Psychiatry 15: 321-9.
12. Chabannes JP, Pelissolo A, Farah S, Gérard D (1998) [Evaluation of the efficacy and safety of amisulpride in the treatment of schizophrenia]. L'Encéphale XXIV: 386-92.
13. Darcourt G, Gérard D, Chabannes J-P (1999) Correlation of Psychosocial Attitude Rating Scale (PARS). XI World Congress of Psychiatry, Abstracts Volume II: 9 (abstract no. FC-05-04).
14. Rein W, Turjanski S (1997) Clinical update on amisulpride in deficit schizophrenia. Int Clin Psychopharmacol 12 (Suppl 2): S19-27.
15. Rein W, L'Héritter C (1999) Treatment-emergent tardive dyskinesta in the long-term treatment of schizophrenia: a comparison of amisulpride and haloperidol. Eur Neuropsychopharmacol 9 (Suppl 5): S282.
16. Marken PA, Haykal RF, Fisher JN (1992) Management of psychotropic-induced hyperprolactinaemia. Clin Pharm 11: 851-6.
17. Ghadirian AM, Chouinard G, Annable L (1982) Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. J Nerv Ment Dis 170: 463-7.
18. Burke MA, McEvoy JP, Ritchie JC (1994) A pilot study of a structured interview addressing sexual function in men with schizophrenia. Biol Psychiatry 35: 32-5.
19. Windgassen K, Wesselmann U, Monktng HS (1996) Galactorrhoea and hyperprolactinemia in schizophrenic patients on neuroleptics: frequency and etiology. Neuropsychology 33: 142-6.
20. Peuskens J, Sienaert P, De Heri M (1998) Sexual dysfunction: the unspoken side effect of antipsychotics. Eur Psychiatry 13 (Suppl 1): 23-30.
21. Wesby R, Bullmore E, Earle J, Heavey A (1996) A survey of psychosexual arousability in male patients on depot neuroleptic medication. Eur Psychiatry 11: 81-6.
22. Margharious W, Goff DC, Amico E (1998) Relationship of gender and menstrual status to symptoms and medication side effects in patients with schizophrenia. Psychiatry Res 77: 159-66.
23. Dickson RA, Glazer WM (1999) Neuroleptic-induced hyperprolactinemia. Schizophr Res 35: S75-86.
24. Maguire GA (2002) Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. J Clin Psychiatry 63 (Suppl 4): 56-62.
25. Meaney AM, O'Keane V (2002) Prolactin and schizophrenia: clinical consequences of hyperprolactinemia. Life Sci 71: 979-92.
26. Coulouvrat C, Dondey-Nouvel L (1999) Safety of amisulpride (Solian®): A review of 11 clinical studies. Int Clin Psychopharmacol 14: 209-18.
27. Wetzel H, Gründer G, Hillert A et al (1998) Amisulpride versus flupenthixol in schizophrenia with predominantly positive symptomatology - a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1/D2-like antagonist. Psychopharmacology 137: 223-32.
28. Puech A, Fleurot O, Rein W and the Amisulpride Study Group (1998) Amisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol, Acta Psychiatr Scand 98: 65-72.
29. Peuskens J, Bech P, Möller JH et al (1999) Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Psychiatry Res 88: 107-17.
30. Möller H-J, Boyer P, Fleurot O et al (1997) Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. Psychopharmacology 132: 396-401.
31. Pijl H, Meinders AE (1996) Bodyweight change as an adverse effect of drug treatment. Mechanisms and management. Drug Saf 14: 329-42.
32. Umbricht D, Kane JM (1996) Medical complications of new antipsychotic drugs. Schizophr Bull 22: 475-83.
33. Allison DB, Mentore JL, Heo M et al (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156: 1686-96.
34. Bernstein JG (1988) Psychotropic drug induced weight gain: mechanisms and management. Clin Neuropharmacol 11 (Suppl 1): S194-206.
35. Fulton B, Goa KL (1997) Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs 53: 281-98.
36. Beasley CM, Tollefson GD, Tran PV (1997) Safety of olanzapine. J Clin Psychiatry 58: 13-7.
37. Nemeroff CB (1997) Dosing the antipsychotic medication olanzapine. J Clin Psychiatry 58 (Suppl 10): 45-9.
38. Brecher M, Geller W (1997) Weight gain with risperidone. J Clin Psychopharmacol 17: 435-6.
39. Claus A, Bollen J, De Cuyper H et al (1992) Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand 85: 295-305.
40. Peuskens J (1995) Risperidone in the treatment of patients with chronic schizophrenia: a multinational, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 166: 712-33.
41. Wetterling T, Müssigbrodt H (1996) Body weight increase: a side effect of zotepine. Nervenarzt 67: 256-61.
42. Borison RL, Arvanitis LA, Miller BG et al (1996) ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 16: 158-69.
43. Taylor DM, McAskill R (2000) Atypical antipsychotics and weight gain - a systematic review. Acta Psychiatr Scand 101: 416-32.
44. Freeman HL (1997) Amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia: three efficacy studies. Int Clin Psychopharmacol 12 (Suppl 2): S11-7.
45. Canal M, Chaufour S, Lavanant C et al (2000) Amisulpride pharmacokinetics: no difference between young and elderly subjects. Eur Neuropsychopharmacol 10 (Suppl 3): S331.
46. Perault MC, Bergougnan L, Paillat A et al (1998) Lack of interaction between amisulpride and lorazepam on psychomotor performance and memory in healthy volunteers. Hum Psychopharmacol Clin Exp 13: 493-500.
47. Mattila MJ, Patat A, Seppälä T et al (1996) Single oral doses of amisulpride do not enhance the effects of alcohol on the performance and memory of healthy subjects. Eur J Clin Pharmacol 51: 161-6.
48. Caton CLM, Showwlong PK, Fleiss JL et al (1985) Rehospitalization in chronic schizophenia. J Nerv Ment Dis 173: 139-48.
49. Green JH (1988) Frequent rehospitalization and noncompliance with treatment. Hosp Community Psychiatry 39: 963-6.
50. Buchanan A (1992) A two-year prospective study of treatment compliance in patients with schizophrenia. Psychol Med 22: 787-97.
51. Addington DE, Jones B, Bloom D et al (1993) Reduction of hospital days in chronic schizophrenia patients treated with risperidone: a retrospective study. Clin Ther 15: 917-26.
52. Souêtre E (1996) Economic impact of improved treatment in schizophrenia. In: Abstracts of the Proceedings of the Xth World Congress of Psychiatry, Madrid, Spain, 23-28 August 1996; 1:123 (Abstract No. S-143-4).
53. Davies A, Langley PC, Keks NA et al (1998) Risperidone versus haloperidol: II. Cost-effectiveness. Clin Ther 20: 196-213.
54. Tunis SL, Johnstone BM, Gibson PJ et al (1999) Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia. J Clin Psychiatry 60 (Suppl 19): 38-45.